Economic evaluations of lung cancer drugs, commissioned by the pharmaceutical industry, began to appear in Brazil between 2008 and 2012, a period during which the FDA was in the process of approving the anaplastic lymphoma kinase inhibitor crizotinib for the treatment of small cell lung cancer, providing prospects for improved survival (43, 48). This evidence concerns the gene ALK and small cell lung carcinoma.